These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22689683)

  • 1. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
    Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
    Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
    Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
    Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
    Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.
    Weisberg E; Sattler M
    Haematologica; 2012 Nov; 97(11):1620-1. PubMed ID: 23125243
    [No Abstract]   [Full Text] [Related]  

  • 5. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
    Guo Y; Li Y; Wang FF; Xiang B; Huang XO; Ma HB; Gong YP
    Int J Biochem Cell Biol; 2019 Jan; 106():8-20. PubMed ID: 30389549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells.
    Tisato V; Norcio A; Celeghini C; Milani D; Gonelli A; Secchiero P
    Clinics (Sao Paulo); 2014 Jan; 69(1):68-74. PubMed ID: 24473562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
    Voltan R; Secchiero P; Corallini F; Zauli G
    Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
    Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
    Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
    Roolf C; Dybowski N; Sekora A; Mueller S; Knuebel G; Tebbe A; Murua Escobar H; Godl K; Junghanss C; Schaab C
    Mol Cell Proteomics; 2017 Jul; 16(7):1365-1376. PubMed ID: 28450419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.
    Haaland I; Opsahl JA; Berven FS; Reikvam H; Fredly HK; Haugse R; Thiede B; McCormack E; Lain S; Bruserud O; Gjertsen BT
    Mol Cancer; 2014 May; 13():116. PubMed ID: 24885082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
    Wang F; Liu Z; Zeng J; Zhu H; Li J; Cheng X; Jiang T; Zhang L; Zhang C; Chen T; Liu T; Jia Y
    Leuk Res; 2015 Dec; 39(12):1421-7. PubMed ID: 26505133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
    Thompson T; Andreeff M; Studzinski GP; Vassilev LT
    Mol Cancer Ther; 2010 May; 9(5):1158-68. PubMed ID: 20406950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
    Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
    Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.
    Kojima K; Konopleva M; Tsao T; Andreeff M; Ishida H; Shiotsu Y; Jin L; Tabe Y; Nakakuma H
    Leukemia; 2010 Jan; 24(1):33-43. PubMed ID: 19946262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
    Vatsyayan R; Singhal J; Nagaprashantha LD; Awasthi S; Singhal SS
    Mol Carcinog; 2013 Jan; 52(1):39-48. PubMed ID: 22006587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.
    Secchiero P; Zerbinati C; Melloni E; Milani D; Campioni D; Fadda R; Tiribelli M; Zauli G
    Neoplasia; 2007 Oct; 9(10):853-61. PubMed ID: 17971905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
    Wergeland L; Sjøholt G; Haaland I; Hovland R; Bruserud Ø; Gjertsen BT
    Mol Cancer; 2007 May; 6():33. PubMed ID: 17498302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.
    Man CH; Lam SS; Sun MK; Chow HC; Gill H; Kwong YL; Leung AY
    Blood; 2014 Apr; 123(16):2530-9. PubMed ID: 24608976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
    Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P
    Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.